Company Profile for BioCryst Pharmaceuticals

--(BUSINESS WIRE)-- BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Additionally, BioCryst has a third product candidate, BCX4208—a next generation PNP inhibitor—in mid-stage trials for the treatment of gout. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company’s Web site at www.biocryst.com.

Company:

  BioCryst Pharmaceuticals
 

Headquarters Address:

2190 Parkway Lake Drive
Birmingham, AL 35244
 

Main Telephone:

205-444-4600
 

Website:

www.BioCryst.com

 

Ticker:

NASDAQ: BCRX

 

Type of Organization:

Public
 

Industry:

Biotechnology
 

Key Executives:

CEO: Jon Stonehouse

CFO: Stuart Grant

Chief Medical Officer: William Sheridan

 

Investor Relations

Contact:

Robert Bennett

Phone:

919-859-7910

Email:

[email protected]



KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.